Sangamo Therapeutics Inc
SGMO0.400USD
+0.047+13.15%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
128.80MMarket Cap
LossP/E TTM
More Details of Sangamo Therapeutics Inc Company
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Sangamo Therapeutics Inc Info
Ticker SymbolSGMO
Company nameSangamo Therapeutics Inc
IPO dateApr 06, 2000
CEOMacrae (Alexander D)
Number of employees183
Security typeOrdinary Share
Fiscal year-endApr 06
Address501 Canal Blvd.
CityRICHMOND
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94084
Phone15109706000
Websitehttps://www.sangamo.com/
Ticker SymbolSGMO
IPO dateApr 06, 2000
CEOMacrae (Alexander D)
Company Executives of Sangamo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
266.20K
-36676.00%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
189.91K
-7721.00%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+25000.00%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+25000.00%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Robert F. Carey
Mr. Robert F. Carey
Independent Director
Independent Director
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. James R. Meyers
Mr. James R. Meyers
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
266.20K
-36676.00%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
189.91K
-7721.00%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+25000.00%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+25000.00%
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alexander D. Macrae, Ph.D.
Dr. Alexander D. Macrae, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
57.80M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 6 hours ago
Updated: 6 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.36%
Renaissance Technologies LLC
2.85%
Two Sigma Investments, LP
1.30%
BlackRock Institutional Trust Company, N.A.
1.27%
Geode Capital Management, L.L.C.
0.92%
Other
90.29%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.36%
Renaissance Technologies LLC
2.85%
Two Sigma Investments, LP
1.30%
BlackRock Institutional Trust Company, N.A.
1.27%
Geode Capital Management, L.L.C.
0.92%
Other
90.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
7.74%
Hedge Fund
5.17%
Investment Advisor/Hedge Fund
2.72%
Individual Investor
1.16%
Research Firm
0.98%
Corporation
0.91%
Other
81.31%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
304
63.00M
18.72%
-49.01M
2025Q3
319
55.42M
16.47%
-39.56M
2025Q2
349
61.18M
25.54%
-60.51M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
2023Q3
436
126.62M
71.56%
-23.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
11.62M
3.45%
+2.24M
+23.90%
Sep 30, 2025
Renaissance Technologies LLC
10.18M
3.03%
+3.34M
+48.88%
Sep 30, 2025
Two Sigma Investments, LP
4.65M
1.38%
+2.57M
+123.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.55M
1.35%
+375.36K
+8.98%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.29M
0.98%
+954.20K
+40.91%
Sep 30, 2025
Biogen Inc
3.25M
0.97%
-11.40M
-77.82%
Aug 14, 2024
Susquehanna International Group, LLP
2.42M
0.72%
+1.65M
+213.01%
Sep 30, 2025
Jane Street Capital, L.L.C.
2.20M
0.65%
+2.20M
--
Sep 30, 2025
Macrae (Sandy)
2.05M
0.61%
-7.49K
-0.36%
Nov 24, 2025
Charles Schwab Investment Management, Inc.
1.54M
0.46%
+257.20K
+20.07%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.62%
iShares Neuroscience and Healthcare ETF
0.28%
Global X Genomics & Biotechnology ETF
0.2%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
State Street SPDR S&P Kensho New Econ Comp ETF
0%
State Street SPDR S&P Biotech ETF
0%
Global X Russell 2000 Covered Call ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.62%
iShares Neuroscience and Healthcare ETF
Proportion0.28%
Global X Genomics & Biotechnology ETF
Proportion0.2%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
State Street SPDR S&P Kensho New Econ Comp ETF
Proportion0%
State Street SPDR S&P Biotech ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
